Clinical intelligence from
seven live data sources

Monitors Kymera, Nurix, C4 Therapeutics, and Plexium for news, filings, and corporate updates.

Tracks active and upcoming clinical trials from Boston-area TPD companies across all registries.

Watches for phase transitions, new IND filings, and partnership announcements from local companies.

Maps competitive positioning across Kymera, Arvinas, C4, Nurix, Monte Rosa, Plexium, and Vividion.

Monitors partnership and licensing activity: Sanofi-Kymera, Gilead-Kymera, Bayer-Vividion, and emerging deals.

Compares PROTAC vs molecular glue approaches: clinical success rates, target coverage, and pharmacology trends.

Monitors trial activity for key immunology degradation targets: STAT6, IRAK4, and IRF5.

Analyzes the trial landscape for atopic dermatitis, asthma, COPD, SLE, and hidradenitis suppurativa.

Synthesizes PubMed literature on inflammation, autoimmune mechanisms, and TPD biology.

Tracks FAERS adverse event reports for immunology drugs and related degrader programs.

Monitors CDK2, EGFR, and BRAF degrader programs across all TPD companies.

Analyzes CCNE1-amplified tumors, resistance mechanisms, and patient selection strategies.

Scouts phase progression for oncology degraders and identifies emerging combination strategies.

Benchmarks oncology degrader pipelines across companies: endpoints, timelines, and differentiation.

Detects signals of new entrants from IND filings, patent applications, and small-registry postings.

Tracks FDA and EMA guidance, breakthrough designations, and accelerated approval pathways for degraders.

Monitors WHO ICTRP, ChiCTR, and non-US registries for trial activity not visible on ClinicalTrials.gov.

Extracts questions, ideas, action items, decisions, and clinical context from the live transcript. Always active during meetings.

FDA/EMA pathways, submission timelines, compliance risks, regulatory precedents, breakthrough designations, and safety signal interpretation.

Competitor pipeline moves, market positioning, differentiation opportunities, patent landscape, and M&A implications detected from meeting discussions.

Endpoint selection, enrollment strategy, adaptive designs, dose optimization, patient stratification, and biostatistical considerations surfaced during meetings.

Partnership signals, deal structures, milestone economics, royalty implications, portfolio strategy, and investor messaging detected in real time.

Searches RDAtlas clinical trial data cross-linked with organizations and investigators.

Monitors rare disease patent filings and IP landscape via RDAtlas patent search.

Tracks government grants and funding for rare disease programs.

Monitors companies and research groups active in rare disease from RDAtlas organization profiles.

Scores target-disease associations using genetic, genomic, and literature evidence.

Maps diseases to tractable targets with evidence breakdowns.

Traces drug-target-disease paths through pharmacology and pathway data.

Tracks new GWAS and functional genomics evidence for targets of interest.

Checks drug-drug interactions, contraindications, and metabolic pathways.

Provides detailed mechanism of action, pharmacodynamics, and pharmacokinetics.

Maps drugs to molecular targets with binding affinity and selectivity data.

Tracks clinical trial registrations, amendments, and results across EU member states.

Monitors EMA scientific opinions, CHMP assessments, and marketing authorization decisions.

Cross-references EU and US trial registrations to identify multi-regional studies and regulatory divergence.

Tracks drug candidates through development phases with status changes and timelines.

Monitors licensing deals, M&A activity, and partnership terms across the industry.

Tracks FDA/EMA submissions, advisory committee dates, PDUFA dates, and approval decisions.

Maps competitive positioning across therapeutic areas with pipeline overlaps.

Assesses clinical significance of genetic variants with submitter consensus and review status.

Tracks new variant submissions and reclassifications for genes of interest.

Identifies clinically actionable variants relevant to trial inclusion/exclusion criteria.

Maps patent families, jurisdictions, and claims across therapeutic areas.

Identifies potentially blocking patents and expiration timelines for drug candidates.

Tracks patent filing trends by company, technology, and therapeutic area.

Connects patent citations to scholarly publications to trace innovation provenance.

Provides likelihood-of-approval (LOA) scores using Biomedtracker historical phase transition data.

Identifies and ranks clinical trial sites by experience, enrollment rates, and investigator track record.

Tracks drug pipeline changes, phase transitions, and development discontinuations.

Provides consensus sales forecasts and peak revenue estimates for drugs and therapeutic areas.

Tracks risk-adjusted NPV and probability-weighted pipeline valuations.

Monitors analyst consensus changes, estimate revisions, and market expectation shifts.

Searches CDD Vault for molecules by name, synonym, or CAS number. Returns registration metadata, batch counts, project assignments, and custom field values.

Retrieves assay protocols and readout data from CDD Vault. Normalizes readout values and flags unnormalized or incomplete results.

Maps internal CDD Vault programs to external clinical assets and trials. Uses crosswalk store for reviewed mappings and flags candidates needing review.

Previews and confirms write-back operations on CDD Vault molecules. Shows old vs new values and enforces approval tokens for all writes.

Broad exploration of CDD Vault contents including molecules, projects, and protocols. Use for first-pass or ambiguous requests.

Creates and updates CDD Vault projects. Admin-only operations requiring elevated permissions and a separate admin token.